Bifonazol

Quick links to important sections

Bifonazol

Selected form

Method of action: Antifungal Broad Spectrum

Treatment option: Hyperhidrosis

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bifonazol

Property Description
Active ingredient Bifonazole (INN)
Form Cream, Solution, Gel, Ointment, Powder (Topical preparations)
Pharmacological class Azole Antifungal Agent, Imidazole Derivative
Common use Topical Antifungal Therapy for superficial skin infections
Origin Synthetic compound

Bifonazol: Definition and Pharmaceutical Classification

Bifonazol, officially designated by its International Non-Proprietary Name (INN) Bifonazole, is a synthetic compound used in localized antifungal therapy. This specific medicine is structurally categorized as an imidazole derivative and functionally belongs to the azole antifungal agent class, reflecting its primary action against fungal pathogens. This classification establishes its fundamental role as a small molecule drug designed to address fungal proliferation on the surface of the skin. This derivative is characterized by its broad-spectrum efficacy against a wide variety of common dermatophytes, yeasts, and molds, which is an integral feature of its pharmacological profile.

Composition and Physical Form of Bifonazol

This agent is manufactured as a single active ingredient product, containing only the compound Bifonazole (C22H18N2) for its therapeutic effect. The drug is made available in several distinct topical preparations for delivery exclusively via the cutaneous route of administration, which notably include a cream base, a liquid solution, a gel, and an ointment. This variety in formulation ensures the active ingredient, suspended within a suitable inert base/vehicle, can be applied to different types of skin conditions, such as dry, cracked skin or moist areas between the toes.

Key Distinctions of Bifonazol’s Antifungal Action

Bifonazol is characterized within its class by its defining dual mode of action, which provides a targeted method for fungal control. This mechanism involves inhibiting two separate enzymatic processes essential for the synthesis of ergosterol, a critical structural component of the fungal cell membrane. This two-point interference relates to the therapeutic result: the medicine exhibits properties that restrict fungal growth (fungistatic property) and possesses the capacity to directly destroy the fungal cells themselves (fungicidal property) against common cutaneous pathogens, a characteristic associated with resolving persistent superficial infections.

What side effects are possible with Bifonazol?

Possible Side Effects and Safety Information

Official regulatory documents classify the majority of possible adverse reactions to topical Bifonazole within the Skin and subcutaneous tissue disorders and General disorders and administration site conditions system-organ classes, reflecting its primary application route. The frequency of most documented adverse events is officially classified as not known, meaning it cannot be reliably estimated from available post-marketing data.


Documented Localized and Cutaneous Reactions

The most frequently cited local reactions include a skin burning sensation and pruritus (itching). Other effects documented at the application site include erythema (redness), eczema, skin irritation, and blister formation. Less frequently observed effects include skin exfoliation (peeling), dry skin, and localized symptoms such as administration site pain or localized peripheral oedema. Most of these cutaneous effects are generally noted as being reversible after discontinuation of the treatment.

Serious Reactions and Safety Considerations

In the Immune system disorders category, systemic hypersensitivity reactions are documented as a rare, serious adverse reaction, which may manifest as a severe rash or swelling. Bifonazole is contraindicated for use in individuals with a known hypersensitivity to the active ingredient or to related imidazole antifungal agents. Safety notes also address the use of the medicine alongside certain oral medications; specifically, an interaction with oral anticoagulant medicine, such as warfarin, is noted as a possibility that may increase the patient’s International Normalised Ratio (INR) and requires monitoring. For pregnant women, use is limited to cases following a thorough benefit-risk evaluation by a medical professional.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for bifonazol addresses overdose primarily in the context of accidental oral ingestion, not typical topical use. Because of the low systemic absorption after correct dermal application, official sources indicate that systemic toxicity is not expected following the intended use of the product.

Documented Overdose Scenarios

Overdose Scenario Expected Clinical Manifestations
Accidental Oral Ingestion Primarily gastrointestinal symptoms, such as nausea and vomiting
Topical Overuse Systemic toxicity is not expected due to low skin absorption

Emergency Actions and Medical Help

Should the entire contents of a tube or other significant quantity be accidentally ingested (swallowed), emergency medical advice should be sought immediately. In such cases, official documents suggest that the management may include the administration of activated charcoal or other supportive measures to manage the resulting gastrointestinal upset and to limit further absorption. Immediate medical consultation is the required action when accidental ingestion occurs. The clinical focus remains on managing non-serious, short-term gastrointestinal effects, as life-threatening systemic collapse is not a documented risk for this product.

Therapeutic Uses of Bifonazol

What Bifonazol Treats: Main Uses and Benefits

Bifonazole is generally used to provide targeted support for common superficial fungal infections, focusing primarily on supporting the process of managing the infection and relieving the associated distress. It is applied across domains where localized skin symptoms may cause significant discomfort and require supportive management. Its application is relevant for the treatment of mycoses of the skin caused by dermatophytes, yeasts, and Pityriasis Versicolor.

This medicine is commonly used for infections like athlete's foot (tinea pedis), ringworm (tinea corporis), jock itch (tinea cruris), as well as skin candidiasis and Pityriasis Versicolor.

Quick Fact: Relief for Itching Bifonazole assists in managing the symptom clusters that may become intense or disruptive, related to inflammatory or irritative states. It may help address distressing manifestations of itching and burning sensations, which often interfere with daily comfort. The key benefit is providing symptomatic relief, which contributes to easing the overall symptom burden.

The medication assists in the process of managing physical damage, such as scaling and cracking, that can accompany fungal growth. This pragmatic support is relevant for active individuals or those in humid environments, helping to stabilize symptoms and providing supportive relief when symptoms interfere with routine activities during acute episodes.

“This pragmatic support is relevant for active individuals or those in humid environments, helping to stabilize symptoms and providing supportive relief when symptoms interfere with routine activities during acute episodes.”

Eligibility and Restrictions for Use

Bifonazol eligibility is defined by regulatory agencies based on documented contraindications and specific population characteristics. The medicine is contraindicated and must not be used by patients with a known hypersensitivity to the active ingredient (bifonazole) or to any of the product's non-active components. Treatment of nappy rash in infants is also formally prohibited.

Conditional use applies to several patient groups. Individuals with a history of allergic reactions to other imidazole antifungal agents (such as clotrimazole) should use the medicine with caution due to potential cross-sensitivity. Furthermore, use in neonates, infants, and toddlers (under 24 months) is restricted and requires medical supervision.

Regarding pregnancy and lactation, the medicine should only be used during pregnancy after a physician assesses the potential benefit against the potential fetal risk. For nursing mothers, a decision must be made to discontinue breastfeeding or discontinue therapy, and the product must not be applied to the chest area. The official regulatory documentation for the topical formulation does not state specific restrictions related to hepatic or renal impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the product's interaction profile around two specific constraints: a formal pharmacokinetic-type interaction with one medicinal product class, and a restriction concerning medical devices.


Documented Pharmacokinetic Interaction

Co-administration of the topical antifungal Bifonazol with oral Warfarin (an anticoagulant) has been associated with a potential for pharmacokinetic interaction

. This interaction may lead to an increase in the International Normalized Ratio (INR), reflecting an enhanced anticoagulant effect. Regulatory authorities mandate that the anticoagulant effect of Warfarin must be closely monitored if Bifonazol is used in patients receiving this therapy. The need for closer monitoring is emphasized when the product is applied under conditions that promote systemic absorption, such as application to a large surface area, broken skin, or under occlusion.


Interaction-Related Restriction

Specific excipients (non-active ingredients) present in the topical Bifonazol formulation may potentially reduce the effectiveness of latex products, including condoms and diaphragms. This physical/chemical restriction applies when the medication is applied to the genital area. This information is included in the official labeling to ensure awareness of this temporary material incompatibility.

Mechanism of Action

Dual Blockade of Fungal Membrane Synthesis

Bifonazol's core mechanism involves the concurrent inhibition of two different fungal enzymes essential for creating ergosterol, the fungal cell membrane's structural lipid. The molecule inhibits the primary target, Lanosterol 14-alpha-demethylase (CYP51A1), and a component of the HMG-CoA Reductase pathway. This dual enzymatic interference both depletes the cell's structural supply and causes the accumulation of toxic sterol intermediates within the cell.


Fungal Cell Cytotoxicity and Growth Arrest

The cascade initiated by the dual enzyme inhibition results in structural and functional damage to the fungal cell membrane, increasing its permeability and causing the leakage of vital cell contents. This process leads to the concentration-dependent fungicidal effect (cell destruction) against key pathogens, complemented by a fungistatic property (growth arrest). The resulting cytotoxicity, which encompasses both properties, is attributed to the dual pathway inhibition.


Local Modulation of Host Tissue Response

Independent of its primary antifungal activity, the molecule exerts a distinct, localized effect on host physiological pathways. This mechanism causes a local downregulation of inflammatory signaling pathways in host tissue, leading to a modulation of the host tissue's inflammatory response.

Dosage and Administration Information

How to Use Bifonazol: General Administration Guidelines

Bifonazol is administered exclusively via the cutaneous route as a topical preparation, commonly available as a 1% w/w cream. The administration protocol is standardized across its therapeutic indications.

Application Regimen and Dosing

The medicine is applied once daily, typically recommended for use at night before retiring. The dosing instruction involves the application of a thin layer to the entire affected area and the immediate surrounding skin.

Feature Guideline (Label-Based)
Application Quantity A small amount, such as a pea-sized quantity, is sufficient for an area the size of the palm.
Pre-application Step Affected skin areas must be washed and dried thoroughly before the cream is applied.
Application Technique The preparation should be gently rubbed in until absorbed.
Missed Dose Rule If a dose is missed, it should be applied as soon as remembered, but a double dose must not be applied.

Duration and Special Use Conditions

Treatment must be carried out for the full duration specified for the condition, even if visible signs of infection have resolved. The typical course for Tinea pedis (athlete’s foot) is three weeks, while Tinea corporis and candidiasis typically require two to three weeks of continuous use.

Use on infants and children requires medical supervision. Additionally, the cream is for external use only and application must avoid the eyes, mouth, and vagina. Occlusive dressings should not be used over the application site unless explicitly directed by a healthcare provider.

Recent Clinical Evidence

Evidence for Superficial Skin and Yeast Infections

Research exploring the use of Bifonazol for common superficial fungal infections—such as Athlete’s foot, Ringworm, and Pityriasis Versicolor—has primarily been applied in Randomized Controlled Trials (RCTs) involving adult populations. These studies examined two main types of outcomes: mycological cure (laboratory confirmation of fungal clearance) and clinical cure (resolution of visible signs and symptoms), in addition to monitoring physical discomfort like itching. Findings describe patterns in which measurements of clinical and mycological clearance were more frequently recorded in the study group compared to the placebo group. However, the evidence quality varies, with many findings derived from older trials where methodologies were not consistently reported.

Studies for Nail Fungal Infection (Onychomycosis)

Research explored the agent's application for nail fungal infections (onychomycosis) within the context of a two-stage treatment process that included preparatory nail management. Studies report how nail conditions evolved in the observed populations when this specific combination regimen was used. It is not yet clear whether the findings describe similar patterns when the agent is used as a standalone topical treatment, as comparative evidence is lacking for monotherapy use.

Long-Term Evidence and Recurrence Assessment

Clinical research usually focuses on the short-term treatment period. While studies monitored for potential recurrence in the short term, long-term effects are not fully established. There is limited information for long-term outcomes and the recurrence rates over extended periods, as studies do not fully characterize the durability of the observed outcomes beyond the immediate post-treatment assessments.

Research in Specialized Patient Groups

The majority of the research has been conducted in adult populations, meaning the results apply only to the populations studied. Data for certain groups remain insufficient, and research exploring short-term symptom changes in specialized patient populations (e.g., children, pregnant individuals) is often more restricted. Research in these contexts is ongoing and may contribute to the broader evidence landscape.

Study Limitations and Remaining Research Gaps

A key research limitation is that the evidence quality varies across studies, with many older trials not meeting modern methodological reporting standards. Sample sizes were modest in some pivotal reports, which can limit the certainty of the findings. Furthermore, comparative evidence is lacking to definitively place this agent within the family of other available topical antifungals. The research evidence highlights what is known — and what is still uncertain regarding long-term individual responses.

Key Studies & References

  1. Bifonazole 1% plus urea 40% in two phases for the treatment of onychomycosis: a multicentre, double-blind, placebo-controlled study
  2. Pharmacological properties and clinical efficacy of bifonazole as a broad-spectrum antifungal agent

Frequently Asked Questions (FAQ)

Common questions about Bifonazol (FAQ)

Q: How long after starting Bifonazol can a person expect to see improvement?

A: Official administration guidelines advise consulting a doctor or pharmacist if symptoms do not improve within seven days of starting the treatment. This guidance provides a reference point for when to seek professional advice if improvement has not been observed.

Q: Is it normal to feel a mild burning or stinging sensation when applying Bifonazol?

A: A skin burning sensation and pruritus (itching) are listed in official documents as among the most frequently cited local reactions that may occur at the site of application. These reactions are typically related to the topical application.

Q: Can Bifonazol be used for fungal infections of the nails (onychomycosis)?

A: While the cream formulation is primarily for superficial skin infections, research has explored the agent’s use for onychomycosis (nail fungal infections). This use was investigated within the context of a specific two-stage treatment process that includes preparatory nail management.

Q: How quickly does Bifonazol penetrate the skin after application?

A: Pharmacokinetic data available in regulatory documents describe the rate of absorption into the skin after a single application. This measurement describes how the active ingredient moves from the skin surface into the necessary layers to exert its effect.

Q: Is the once-daily application due to how long Bifonazol stays active in the skin?

A: The once-daily regimen is supported by the drug’s pharmacokinetic properties. These properties show that the active substance achieves a lasting concentration in the layers of the skin needed for its antifungal action over a 24-hour period.

Q: Is Bifonazol available over-the-counter (OTC) or only by prescription?

A: The regulatory status of Bifonazol varies by country. While some formulations are widely used in the self-care sector, other specific products in certain jurisdictions are classified as medicines available only by prescription.

Q: Is Bifonazol appropriate for use on the face or near the eyes?

A: Official guidelines state the cream is for external use only, and application is restricted from the eyes, mouth, and vagina. This is noted in official labeling to ensure awareness of its intended route of administration.

Q: Does Bifonazol have a local anti-inflammatory effect on the skin?

A: The molecule has been described in regulatory-adjacent scientific literature as causing a local downregulation of inflammatory signaling pathways in host tissue. This mechanism leads to a modulation of the host tissue’s inflammatory response, independent of its antifungal action.

Q: What is the role of the ingredients other than bifonazole in the cream/ointment?

A: Non-active ingredients (excipients) form the base or vehicle for the cream. Specific excipients are noted because they may potentially cause local skin reactions, such as mild irritation, and may also reduce the effectiveness of latex products.

Q: What should be done if the fungal infection symptoms worsen after starting Bifonazol?

A: Official information advises consulting a doctor or pharmacist if symptoms do not improve within seven days of starting the treatment. This serves as the timeframe established in the guidance for evaluating efficacy.

Q: Why is it important to continue using Bifonazol even after the symptoms disappear?

A: The full treatment duration is described in official guidance as necessary to achieve mycological cure. This means ensuring complete clearance of the fungus deep within the skin, which helps to reduce the likelihood of the infection returning.

Q: Is there any research evidence showing Bifonazol works well for athlete's foot (tinea pedis)?

A: Research exploring its use for Athlete’s foot has reported that measures of mycological cure (fungal clearance) and clinical cure (symptom resolution) were more frequently recorded in study participants compared to placebo groups.

Q: Why is proper foot hygiene important when treating athlete's foot with Bifonazol?

A: The administration guidelines state that the affected skin areas must be washed and dried thoroughly before application. This step is considered supportive of the medicine’s action and essential for successful treatment.

Q: Does Bifonazol cream contain benzyl alcohol, and is that safe?

A: Some Bifonazol cream formulations contain benzyl alcohol as an excipient. This ingredient is noted in regulatory documents as a potential cause of allergic reactions and mild local irritation in some individuals.

Q: Is Bifonazol suitable for use on skin that is blistered or broken?

A: Regulatory documents note that use on broken and damaged skin may lead to higher systemic absorption of the drug. This is an important consideration for patients taking concurrent oral medication, such as Warfarin, which requires closer monitoring.

Q: Is Bifonazol used for the treatment of tinea versicolor?

A: Yes, Bifonazol is indicated in official documents for the treatment of pityriasis versicolor, which is also commonly known as tinea versicolor.

Q: If I am allergic to other 'azole' antifungals, can I still use Bifonazol?

A: Official documents advise that patients with a history of hypersensitivity reactions to other imidazole antifungal agents (such as clotrimazole) should be aware that the product carries a regulatory warning and should be used with caution due to the potential for cross-sensitivity.

Q: What is the purpose of applying the cream to the area surrounding the infected skin?

A: The official regimen requires application of the cream to the affected area and the immediate surrounding skin. This is intended to ensure all potentially infected areas, including those that are not yet showing visible symptoms, receive treatment.

Q: Does Bifonazol cause dryness or peeling of the skin, and is that a bad sign?

A: Official documents list skin exfoliation (peeling) and dry skin as possible local reactions. These effects are generally described as being reversible after discontinuation of the treatment.

Q: Is there a maximum amount of time Bifonazol can be used for?

A: Official documents define the typical course duration for conditions like Athlete's foot as two to three weeks. If symptoms persist beyond seven days, official information advises consulting a physician or pharmacist.

Q: Can Bifonazol be used to treat oral or vaginal fungal infections?

A: Official documents state the product is not for vaginal use. The cream is for external use only and application is restricted from sensitive internal areas such as the mouth and vagina.

Q: Does using Bifonazol make a person feel tired or affect driving ability?

A: Official regulatory information states that Bifonazol cream is considered to have no or negligible influence on the ability to drive or use machines.

Q: Is Bifonazol used for fungal infections in the groin area, like jock itch (tinea cruris)?

A: Official documents indicate the product is used to treat tinea infections (ringworm), a category which includes infections found in the groin, such as jock itch (tinea cruris).

Q: Are there different strengths or formulations of Bifonazol, like a powder or solution?

A: Bifonazol is manufactured in several different topical preparations for delivery via the cutaneous route. These formulations commonly include a cream, a liquid solution, a gel, and an ointment.

How should Bifonazol be stored and disposed of?

Bifonazole Storage and Disposal

Bifonazole topical preparations must be stored according to regulatory specifications to ensure product stability and safety.

Storage Requirements

  • Environmental Constraints: The medicine must be stored in a cool, dry place and be protected from direct sunlight and excessive heat, with some regulatory documents specifying temperatures not exceeding 30 C.
  • Container and Stability: The product must remain in its original container/carton and be kept tightly closed. Specific cream formulations are labeled for use for up to 16 months after opening, and the medicine should not be used past the expiry date.
  • Child Safety: It is a mandatory requirement to keep the medicine out of the sight and reach of children.

Disposal Instructions

  • Waste Handling: Unused or expired Bifonazole must not be disposed of via wastewater or general household waste. Disposal must adhere strictly to local requirements, and the user is instructed to ask a pharmacist for guidance on proper pharmaceutical waste handling to protect the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Bifonazol found in:

A-Z Index: